Roy D. Baynes - 11 Mar 2025 Form 3 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Roy D. Baynes
Issuer symbol
NRIX
Transactions as of
11 Mar 2025
Transactions value $
$0
Form type
3
Filing time
13 Mar 2025, 16:07:26 UTC
Previous filing
12 Feb 2025
Next filing
29 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NRIX Director Stock Option (right to buy) 11 Mar 2025 Common Stock 10,000 $9.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 1/2 of the total shares on April 1, 2024, and vests as to the remaining 1/2 of the total shares on April 1, 2025, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

Exhibit 24 - Power of Attorney